Zucapsaicin
Alternative Names: cis-Capsaicin; Civamide; Civamide 0.075% cream - Winston Pharmaceuticals; Civanex; Civanex Nasal Solution; Dolorac Nasal Solution; Neuroderm Patch; ZuactaLatest Information Update: 14 Apr 2021
At a glance
- Originator Winston Laboratories
- Developer Sanofi; Winston Laboratories; Winston Pharmaceuticals
- Class Catechols; Monounsaturated fatty acids; Polyunsaturated alkamides; Solanaceous alkaloids
- Mechanism of Action TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pain
- Phase II Keratoconjunctivitis sicca
- No development reported Cluster headache; Crohn's disease; Migraine; Postherpetic neuralgia; Rhinitis
Most Recent Events
- 14 Apr 2021 Winston Laboratories plans a phase III trial in Cluster headache (Prevention, In adults, In the elderly) (Intranasal) in November 2021 (NCT01341548)
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 09 Jun 2015 No recent reports on development identified - Phase-II for Crohn's disease in USA (PO, capsule)